The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. In Vivo reviews the leading drug developers in this space.

The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.

The next frontier for cell therapy is solid tumors – and of the many attempts to move from liquid to solid tumors, tumor infiltrating lymphocytes and other CAR-T constructs are some of the most promising. 

AstraZeneca’s pact with the UK-based artificial intelligence leader BenevolentAI, in April 2019, is one component in a string of recent deals that have highlighted big pharma’s desire to embed AI and machine learning within the R&D process. In total, 13 such collaborations have been tracked in the past 24 months, according to the Strategic Transactions database.

INFOGRAPHIC: major alliance deals focused on artificial intelligence and machine learning, signed by pharmaceutical companies over the past two years.

Almost a decade on since the first approval for an immuno-oncology therapy, In Vivo analyzes the current landscape, the evolution of combination cancer treatments that use the immune system to target disease and future commercial potential for the market.